2019 Management of Ulcerative Colitis: Where, When, Who, and What Now?Premiere Date: Friday, March 15, 2019
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 31, 2020
|David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
|Miguel Regueiro, MD, AGAF, FACG, FACP
Professor and Chair
Department of Gastroenterology, Hepatology & Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Ulcerative colitis (UC) is a progressive disease whose clinical, functional, and psychosocial impact can be comparable to that of Crohn's disease (CD). While the management of UC has for some time focused on simple control of symptoms, strategies for managing UC have progressed, with treatment goals shifting from resolution of symptoms to full control of the disease, with a final aim of halting or preventing disease progression. Management strategies have shifted from a step-up to a top-down approach to achieve these goals, which include mucosal healing, prevention of complications, surgery, and disability, and restoration of quality of life. This means that immunosuppressants and/or biologics are used earlier during the course of the disease; however, it leads to challenges for clinicians in identifying which patients will benefit from early intervention and which will derive minimal benefit.
The American Gastroenterology Association (AGA) Care Pathways provide practical tools to help providers risk-stratify their patients with inflammatory bowel disease (IBD) into those with low or moderate/high-risk disease. This stratification helps identify the most appropriate therapy for each patient that will lead to low disease activity or endoscopic remission. Unfortunately, several gaps have been noted in these areas. Clinicians are not appropriately using biologic agents for the treatment of UC and personalized plans such as the UC Care Pathway are often underutilized.
In this CME Outfitters enduring activity, expert faculty will discuss risk stratification in patients with UC, incorporation of biologies into personalized treatment plans, and integrating the Clinical Care Pathway and real-world data into treatment algorithms.
At the end of this CE activity, participants should be able to:
- Apply approaches to identify moderate- to high-risk patients with UC in clinical practice.
- Select appropriate biologic therapy for individual patients with UC, taking into account disease burden, severity, treatment efficacy, safety, personalized risk/benefit profiles, and patient preference.
- Integrate evidence-based guidelines and findings from real-world studies into management plans for patients with UC that factor in treatment goals, initial therapy, continuous monitoring, and medication adjustments as needed.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe approaches to identify moderate- to high-risk patients with UC in clinical practice.
- Identify appropriate biologic therapy for individual patients with UC, considering disease burden, severity, treatment efficacy, safety, personalized risk/benefit profiles, and patient preference.
- Explain evidence-based guidelines and findings from real-world studies that can be used in management plans for patients with UC that factor in treatment goals, initial therapy, continuous monitoring, and medication adjustments.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with ulcerative colitis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Rubin reports that he receives grants from Abbvie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Shire; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Abbvie Inc.; AbGenomics; Allergan; Arena Pharmaceuticals, Inc.; Biomica; Eli Lilly and Company; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Pfizer Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and TARGET PharmaSolutions, Inc. He receives other financial or material support as a member of the Board of Trustees for the American College of Gastroenterology; the Co-Founder, CFO of Cornerstones Health, Inc. (non-profit); and as Co-Founder ofGoDuRn, LLC.
Dr. Regueiro reports that he receives research support form Abbvie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory boards and a consultant for Abbvie Inc.; Allergan; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kate Nelson, PHD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).